FPSIR predicts clinical therapeutic responses and survival outcomes in patients with metastatic colorectal cancer undergoing first-line bevacizumab-containing chemotherapy

Key Points

FPSIR was identified as a strong biomarker predicting clinical efficacy and prognosis.
Patients with metastatic colorectal cancer undergoing bevacizumab-containing chemotherapy showed promising outcomes based on FPSIR levels.
Analysis assessed clinical efficiency using FPSIR as a predictive tool within a cohort of mCRC patients.
The findings highlight a significant step toward personalized treatment in advanced colorectal cancer.

Abstract

Pretreatment FPSIR was identified as a robust biomarker for predicting clinical efficacy and prognosis in mCRC patients receiving first-line Bev/CT, providing a promising strategy to address the long-standing challenge of treatment stratification.

Bookmark

View Full Paper

Cite This Study

Li et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75b87c6e9836116a22f56 https://doi.org/https://doi.org/10.3389/fimmu.2026.1683928

Bookmark

View Full Paper